No Data
An new low in eighteen years! Tonghua Dongbao Pharmaceutical expects last year's net income to decline by more than 90% year-on-year, and Q4 performance may not meet expectations | Interpretations
① Affected by the decline in sales revenue due to product price reductions, as well as the termination of research and development projects, Tonghua Dongbao Pharmaceutical expects that its net income attributable to the parent for 2024 will decrease by more than 90% year-on-year. ② Compared to Q4, net income saw a decline quarter-on-quarter, and may not have met the company's previous expectations.
Sales growth of core varieties: REMEGEN's revenue in 2024 is expected to increase by more than 50% year-on-year, but it has not yet achieved profitability.
① The company has increased its R&D investment, while sales revenue of Tai Tasi Pu and Vidi Situt Monoclonal Antibody has grown rapidly, with the product gross margin continuing to rise and the sales expense ratio significantly decreasing. Therefore, it is expected that the company will report a net loss in 2024, showing a trend of reduced losses; ② The company's Phase III clinical trial for IgAN of Tai Tasi Pu in China has concluded, and data readout is expected in the first half of 2025.
The sales growth of the Paigebin product drives performance increase, with Xiamen Amoytop Biotech achieving a new high in net profit in Q4.
① With the continuous upgrade of hepatitis B chronic prevention and treatment guidelines and the ongoing accumulation of clinical cure scientific evidence, cognitive awareness will be promoted, and the number of patients accepting treatment will show an upward trend; ② Interferon has common side effects such as flu-like symptoms, and relatively, patients have a greater workload in treatment and management, which may affect the treatment choices between doctors and patients.
The growth of the diagnosis Sector does not hide the performance decline of Beijing Wantai Biological Pharmacy Enterprise; the Net income in 2024 may hit a new low since its listing. | Interpretations
① Beijing Wantai Biological Pharmacy Enterprise issued a performance reduction announcement, expecting that the net income attributable to the parent company in 2024 will decrease by more than 90% year-on-year; ② The main reason is the significant decline in income and profits from the vaccine Sector, leading to a net loss; ③ In Q4, the company incurred losses again, but the loss amount narrowed compared to the same period in 2023.
WUXI XDC's net income for 2024 is expected to increase by 260%. WUXI APPTEC recently cashed out 2.4 billion Hong Kong dollars at a high point | Quick read of the announcement.
In 2024, WUXI XDC expects total revenues, Net income, and adjusted Net income to grow by over 85%, 260%, and 170% year-on-year, respectively; According to the latest data from Frost & Sullivan, it is projected that by 2030, the Global market size for ADC and XDC will reach 66.2 billion US dollars.
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
SpyderCall OP : @102640653
102640653 SpyderCall OP : If Shanghai market starts with bullishness trend it will definitely lend support to the hangseng index which had been hit quite badly in recent weeks. Hopefully the bullishness in Shanghai stands strong . Good luck
MonkeyGee : This is China's 2008!
102489169 : Agreed! Follow the trends. Invest $ that we understand, can afford to lose and know when to cut loss. Good advice.
股海踏浪 : Volume comes first before price. There was a time when a real big market didn't come out of a huge amount at the bottom? But now this amount is just a small rebound.